Citius Pharmaceuticals, Inc. (NasdaqCM: CTXR)
Health Care · Pharmaceuticals · US
$0.58
-4.13% today · -52.4% 1Y
Citius Pharmaceuticals, Inc. (NasdaqCM: CTXR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $16.48M and employs 23 people.
Over the last twelve months the share price has lost 52.4%, trading between 0.47 and 2.19.
Tweenvest scores Citius Pharmaceuticals, Inc. across four factors: quality 27/100, value 54/100. Its strongest factor is value.
CTXR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.48M
- Revenue (TTM)
- $7.11M
- P/E
- —
- EPS
- -2.12
- Dividend yield
- —
- Beta (5Y)
- 0.99
- 52-week high
- $2.19
- 52-week low
- $0.47
- Avg volume (3M)
- —
- Shares outstanding
- 27.45M
- Employees
- 23
- Next earnings
- —
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- ISIN
- US17322U3068
- Founded
- 2007
- Listed since
- Oct 2, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.70 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.02 | -0.74% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.20 | +0.36% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.